Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge is advising Nytida in connection with merger with the Solhaga Group
Mandate

Vinge is advising Nytida in connection with merger with the Solhaga Group

January 25, 2016

Vinge is advising Nytida, which is part of Ambea, in connection with the merger with Solhagagruppen (the “Solhaga Group”).

Nytida intends to merge with the Solhaga Group. Nytida and the Solhaga Group possess considerable experience and expertise within the fields of functional impairment and the Solhaga Group specializes in the fields of neuropsychiatric and psychiatric impairment and reduced development. Both Nytida and the Solhaga Group conduct operations throughout a large part of Sweden and provide accommodation, schooling, short-term accommodation and daytime activities. The Solhaga Group also conducts operations in Norway.

Closing of the transaction is subject to the customary approval of the relevant competition authority.

Vinge’s team consisted of, among others, partners Christina Kokko, Jonas Johansson, Louise Brorson Salomon and Marcus Glader together with associates Linda Sengul, Maria Dahlin, Albert Wållgren, Anna-Maria Terzi, Emil Fahlén Godö and Anne Wijkman.

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

 Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

 Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025